A new editorial section was published in 16 Oncotarget On 16 July, 2025, the title “MicroRNAS in Soft Tissue Sarcoma: State of the Art and Barrier to Translation”.

In this article, Elisavata of Ohio State University. Titerina, Alesandro La Ferlita, and Joal D. Bean discusses the role of microRNA in the soft tissue sarcoma (STS), a rare and diverse groups of cancer, which begin in connective tissues such as bone or fat. The author explains how these small molecules control cancer-related processes and highlight their ability as a non-invasive biomarker for diagnosis and monitoring. They also underline the main challenges that need to be addressed before using microRNA-based strategies in clinical settings.

Soft tissue sarcoma consists of more than 50 sub -avoidance, which makes accurate diagnosis and effective treatment difficult. Editorial explains how microRNA affect cancer’s growth, spread and reaction to treatments. Because microRNAs are stable in body fluids such as blood and saliva, they can be used to help in early detection and treatment decisions. For example, some groups of microRNA are associated with how patients are responded to to specific drugs, which show their ability as a tool for accurate therapy.

“For example, MIR-17-92 and MIR-106B-25 clusters are associated with sensitivity or resistance to the eibulin in STS.”

The author also suggests that microRNAS can help differentiate between types of tumors that are often difficult to distinguish, such as benign lipomas and malignant liposarcoma. It is important to identify these differences to guide the decisions of treatment. Specific patterns of microRNA expression in blood samples can enable physicians to make a quick and more reliable diagnosis without the need for aggressive procedures. Beyond his clinical role, MicroRNAS is also being discovered as medical equipment, but it is challenging for patients to apply microRNA-based treatments. These molecules can act as cancer promoters or mitigates based on environment, which complicates the development of safe and targeted remedies. However, new delivery methods such as lipid nanopartanes show accurate and promise to improve safety.

Overall, microRNAs are emerging as an important focus in STS research, offering new possibilities to diagnose, diagnose, diagnose and to lead to treatment. As researchers continue to resolve current challenges, these small molecules can become valuable tools to improve cancer care.